Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol

Chandni Bardolia; Nishita Shah Amin; Jacques Turgeon

doi:10.3389/fcvm.2021.789931

Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol

Front Cardiovasc Med. 2021 Nov 17:8:789931. doi: 10.3389/fcvm.2021.789931. eCollection 2021.

Authors

Chandni Bardolia¹, Nishita Shah Amin¹, Jacques Turgeon^{2

3}

Affiliations

¹ Office of Translational Research and Residency Programs, Tabula Rasa HealthCare, Moorestown, NJ, United States.
² Precision Pharmacotherapy Research and Development Institute, Tabula Rasa HealthCare, Lake Nona, FL, United States.
³ Faculty of Pharmacy, Université de Montréal, Montréal, QC, Canada.

Abstract

Low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for the development of atherosclerotic cardiovascular disease. Statins have been the gold standard for managing cholesterol levels and reducing the risks associated with atherosclerotic cardiovascular disease; however, many patients do not achieve their cholesterol goals or are unable to tolerate this drug class due to adverse drug events. Recent studies of non-statin cholesterol lowering drugs (i.e., ezetimibe, PCSK9 inhibitors) have demonstrated cardiovascular benefits; and new drugs [i.e., bempedoic acid (BDA), inclisiran] have produced promising results in pre-clinical and clinical outcome trials. This narrative review aims to discuss the place in therapy of ezetimibe, PCSK9 inhibitors, BDA, and inclisiran and describe their relative pharmacokinetic (PK) profiles, efficacy and safety as monotherapy and combination therapy, and cardiovascular benefit(s) when used for hypercholesterolemia.

Keywords: PCSK9 inhibitors; alirocumab; bempedoic acid; evolocumab; ezetimibe; inclisiran.

Publication types

Review